A compound of formula (II): ** Formula ** stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof, wherein: Ar is C6-C10 aryl substituted by 0-5 R3; C5-C10 cycloalkenyl substituted by 0-5 R3; or 5-14 membered heteroaryl group substituted with 0-5 R3, wherein said heteroaryl group comprises one, two, or three heteroatoms selected from N, O, S or Se; Y is -CH2-, -CH (OCH3) -, or -CH2CH2-; R1 is C (>; = O) NR12R13; R2 is selected from H, F, Cl, Br, I, OR16, OR25, NR17R18, NHOH, NO2, CN, CF3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C (>; = O) R16 , C (>; = O) OR16, OC (>; = O) R16, C (>; = O) NR17R18, NR15C (>; = O) R16, NR15CO2R16, OC (>; = O) NR17R18, NR15C (>; = S) R16 , SR16; S (>; = O) R16; and S (>; = O) 2R16; alternatively, two R2groups can be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group; R3 is selected from H, F, Cl, Br, I, OR16, OCF3, OR25, NR17R18, NHOH, NO2, CN, CF3, CH2OR16, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3- cycloalkyl C7, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered heteroaryl, C7-C10 arylalkyl, C (>; = O) R16, C (>; = O) OR16, OC (>; = O) R16, C (>; = O) NR17R18, NR15C (>; = O) R16, NR15CO2R16, OC (>; = O) NR17R18, NR15C (>; = S) R16, SR16; S (>; = O) R16; S (>; = O) 2R16, and NR15S (>; = O) 2R16; alternatively, two R3 groups can be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group; R4 and R5 are H; R12 and R13 at each occurrence are each independently selected from H, C1-C6 alkyl substituted with 0-3 R20 and C6-C10 aryl substituted with 0-3 R20; alternatively, R12 and R13, together with the nitrogen to which they are attached, form a 3-7 membered heterocyclic ring substituted with 0-3 R20; R15 at each occurrence is independently selected from H and C1-C6 alkyl; R16 at each occurrence is independently selected from H, C1-C6 alkyl, and C6-C10 aryl; R17 and R1